Keywords
MedicineScopusRofecoxibCelecoxibNaproxenRheumatoid arthritisClinical trialNonsteroidalRandomized controlled trialInternal medicineAlternative medicineMEDLINECyclooxygenasePathology
Affiliated Institutions
Related Publications
Cardiovascular Risk and Inhibition of Cyclooxygenase
This review confirms the findings from randomized trials regarding the risk of cardiovascular events with rofecoxib and suggests that celecoxib in commonly used doses may not in...
Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee.
Within the context of a double blind randomized controlled parallel trial of 2 nonsteroidal antiinflammatory drugs, we validated WOMAC, a new multidimensional, self-administered...
Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective
Owing to the efficacy in reducing pain and inflammation, non-steroidal anti-inflammatory drugs (NSAIDs) are amongst the most popularly used medicines confirming their position i...
Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: A double‐blind, randomized, placebo‐controlled trial
Abstract Objective To determine whether patients with undifferentiated arthritis (UA; inflammatory, nontraumatic arthritis that cannot be diagnosed using current classification ...
Publication Info
- Year
- 2002
- Type
- letter
- Volume
- 360
- Issue
- 9346
- Pages
- 1620-1622
- Citations
- 35
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
35
OpenAlex
Cite This
Marissa Lassere,
Kent Johnson
(2002).
The power of the protocol.
The Lancet
, 360
(9346)
, 1620-1622.
https://doi.org/10.1016/s0140-6736(02)11652-7
Identifiers
- DOI
- 10.1016/s0140-6736(02)11652-7